Introducing MedViewTV ASH 2017 CLL Report & Video Interviews. Click to view late-breaker session with Dr. John Seymour and the MURANO Study

On behalf of Dr. Carolyn Owen (CLiC Chair) we wish to share MedViewTV and its inaugural Report from the Annual Meeting of the American Society of Hematology (ASH) Atlanta, Georgia / December 9-12, 2017, A New Era of Chemotherapy-free Treatments Emerges for Chronic Lymphocytic Leukemia (CLL) with permission from the Medical Education  Network (MedNet).

Atlanta – The recent approvals of many effective, well-tolerated novel agents for chronic lymphocytic leukemia (CLL) have changed the treatment landscape. Researchers are learning how best to sequence and potentially combine novel agents, including ibrutinib, idelalisib, and venetoclax, both with respect to chemo-immunotherapy and other novel agents. A handful of combination and single-agent CLL therapies show promising results, according to reports at ASH 2017. A major aim of CLL treatment is to eradicate detectable minimal residual disease (MRD), which is associated with improved outcomes regardless of the therapy used to achieve it. Deep remissions, including MRD negativity may be achieved with the added benefit of fixed duration of therapy. A consistent safety profile is also important to expand therapy to as many patients as possible … (more)

This week we feature coverage of the ASH 2017 Late-breaker session with Dr. John Seymour and the MURANO Study. To view, click here: http://bit.ly/2pqSLog